On May 25, 2012, Sucampo Pharmaceuticals, Inc., or the Company, held its Annual Meeting of Stockholders at the Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, Maryland 20814. A total of 14,275,735 shares of class A common stock, par value $0.01, and 26,191,050 shares of class B common stock, par value $0.01, or approximately 96.6% of the 41,895,364 shares of common stock outstanding and entitled to vote at the Annual Meeting, were present in person or by proxies. The final voting results for each of the proposals submitted to a vote of Company stockholders at the Annual Meeting are set forth below.

Proposal 1. Election of Directors. Seven members were nominated by the Board of Directors for election as directors of the Company, each to hold office for a term of one year expiring at the 2013 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified. Each nominee was an incumbent director, no other person was nominated, and each nominee was elected. The votes cast for, against, broker no-vote, or withheld with respect to each nominee were as follows:

      Nominee               For            Against         Withheld      Broker Non-Vote

Ryuji Ueno, M.D.,         273,104,624               -           44,604          3,037,007
PH.D., PH.D.
William L. Ashton         273,109,558               -           39,670          3,037,007
Anthony C. Celeste        273,109,498               -           39,730          3,037,007
Gayle R. Dolecek          272,921,460               -          227,768          3,037,007
Daniel P. Getman          273,114,090               -           35,138          3,037,007
Sachiko Kuno, PH.D.       272,921,678               -          227,550          3,037,007
Timothy I. Maudlin        273,109,558               -           39,670          3,037,007

Proposal 2. The ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2012.

Proposal 3. The approval of, on an advisory basis, the compensation of the Company's named executive officers.

273,127,978 10,645 10,605 3,037,007